S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:ATOS

Atossa Therapeutics Stock Forecast, Price & News

$1.25
0.00 (0.00 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$1.14
Now: $1.25
$1.36
50-Day Range
$0.85
MA: $1.09
$1.76
52-Week Range
$0.76
Now: $1.25
$5.08
Volume624,929 shs
Average Volume19.57 million shs
Market Capitalization$13.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Atossa Therapeutics logo

MarketRank

Overall MarketRank

1.31 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATOS
CUSIPN/A
Phone206-325-6086
Employees4

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.37 per share

Profitability

Net Income$-17,240,000.00

Miscellaneous

Market Cap$13.12 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
$1.25
0.00 (0.00 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atossa Therapeutics (NASDAQ:ATOS) Frequently Asked Questions

How has Atossa Therapeutics' stock been impacted by Coronavirus?

Atossa Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATOS stock has increased by 42.0% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19
.

Is Atossa Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atossa Therapeutics stock.
View analyst ratings for Atossa Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Atossa Therapeutics?

Wall Street analysts have given Atossa Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atossa Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Atossa Therapeutics' next earnings date?

Atossa Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Atossa Therapeutics
.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its earnings results on Wednesday, November, 18th. The company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.01.
View Atossa Therapeutics' earnings history
.

When did Atossa Therapeutics' stock split? How did Atossa Therapeutics' stock split work?

Atossa Therapeutics's stock reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Therapeutics stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for ATOS?

2 brokers have issued twelve-month price objectives for Atossa Therapeutics' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Atossa Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 500.0% from the stock's current price.
View analysts' price targets for Atossa Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Atossa Therapeutics?

Atossa Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,800,000 shares, an increase of 529.6% from the December 15th total of 444,700 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is currently 1.2 days.
View Atossa Therapeutics' Short Interest
.

Who are some of Atossa Therapeutics' key competitors?

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia (NOK).

Who are Atossa Therapeutics' key executives?

Atossa Therapeutics' management team includes the following people:
  • Dr. Steven C. Quay, Chairman, CEO & Pres (Age 69, Pay $919.59k)
  • Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 56, Pay $629.18k)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs

What is Atossa Therapeutics' stock symbol?

Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."

How do I buy shares of Atossa Therapeutics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atossa Therapeutics' stock price today?

One share of ATOS stock can currently be purchased for approximately $1.25.

How big of a company is Atossa Therapeutics?

Atossa Therapeutics has a market capitalization of $13.12 million. Atossa Therapeutics employs 4 workers across the globe.

What is Atossa Therapeutics' official website?

The official website for Atossa Therapeutics is www.atossagenetics.com.

How can I contact Atossa Therapeutics?

Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.